{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:04:50Z","timestamp":1793059490877,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46574-y","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:38:16Z","timestamp":1776422296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aspirin-related hemorrhagic complications in pregnancy: a nationwide French cohort study (ASPREG)"],"prefix":"10.1038","volume":"16","author":[{"given":"V.","family":"Tsatsaris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Beeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Alessandrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Goffinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Y.","family":"Ancel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chouchana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Treluyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"46574_CR1","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S0140-6736(85)92207-X","volume":"325","author":"M Beaufils","year":"1985","unstructured":"Beaufils, M., Donsimoni, R., Uzan, S. & Colau, J. C. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet 325, 840\u2013842 (1985).","journal-title":"Lancet"},{"key":"46574_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJM199803123381101","volume":"338","author":"S Caritis","year":"1998","unstructured":"Caritis, S. et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N. Engl. J. Med. 338, 701\u2013705 (1998).","journal-title":"N. Engl. J. Med."},{"key":"46574_CR3","doi-asserted-by":"crossref","unstructured":"CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet Lond. Engl. 343, 619\u2013629 (1994).","DOI":"10.1016\/S0140-6736(94)92633-6"},{"key":"46574_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1046\/j.1471-0528.2003.t01-1-02097.x","volume":"110","author":"D Subtil","year":"2003","unstructured":"Subtil, D. Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: The Essai R\u00e9gional Aspirine M\u00e8re-Enfant study (Part 2). BJOG Int. J. Obstet. Gynaecol. 110, 485\u2013491 (2003).","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"46574_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/bmj.322.7282.329","volume":"322","author":"L Duley","year":"2001","unstructured":"Duley, L., Henderson-Smart, D., Knight, M. & King, J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: Systematic review. BMJ 322, 329\u2013333 (2001).","journal-title":"BMJ"},{"key":"46574_CR6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.7326\/M13-2844","volume":"160","author":"JT Henderson","year":"2014","unstructured":"Henderson, J. T. et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: A systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 160, 695\u2013703 (2014).","journal-title":"Ann. Intern. Med."},{"key":"46574_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ajog.2017.11.561","volume":"218","author":"S Roberge","year":"2018","unstructured":"Roberge, S., Bujold, E. & Nicolaides, K. H. Aspirin for the prevention of preterm and term preeclampsia: Systematic review and metaanalysis. Am. J. Obstet. Gynecol. 218, 287-293.e1 (2018).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"46574_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/AOG.0b013e3181e9322a","volume":"116","author":"E Bujold","year":"2010","unstructured":"Bujold, E. et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-analysis. Obstet. Gynecol. 116, 402\u2013414 (2010).","journal-title":"Obstet. Gynecol."},{"key":"46574_CR9","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(07)60712-0","volume":"369","author":"LM Askie","year":"2007","unstructured":"Askie, L. M., Duley, L., Henderson-Smart, D. J. & Stewart, L. A. Antiplatelet agents for prevention of pre-eclampsia: A meta-analysis of individual patient data. Lancet 369, 1791\u20131798 (2007).","journal-title":"Lancet"},{"key":"46574_CR10","unstructured":"US Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality frompreeclampsia: preventive medication. Available at: https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/RecommendationStatementFinal\/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication (accessed 2026)."},{"key":"46574_CR11","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists (ACOG). Low-dose aspirin use during pregnancy: ACOGCommittee Opinion No. 743. Obstet. Gynecol. 132, e44\u2013e52 (2018).","DOI":"10.1097\/AOG.0000000000002708"},{"key":"46574_CR12","unstructured":"National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. Available at: https:\/\/www.nice.org.uk\/guidance\/ng133 (accessed 2026)."},{"key":"46574_CR13","doi-asserted-by":"crossref","unstructured":"Wheeler, S. M., Myers, S. O., Swamy, G. K. & Myers, E. R. Estimated prevalence of risk factors for preeclampsia among individuals giving birth in the US in 2019. JAMA Netw. Open 5, e2142343 (2022).","DOI":"10.1001\/jamanetworkopen.2021.42343"},{"issue":"95","key":"46574_CR14","first-page":"e1","volume":"224","author":"R Hastie","year":"2021","unstructured":"Hastie, R. et al. Aspirin use during pregnancy and the risk of bleeding complications: A Swedish population-based cohort study. Am. J. Obstet. Gynecol. 224(95), e1-95.e12 (2021).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"46574_CR15","doi-asserted-by":"crossref","unstructured":"Coll\u00e8ge National des Gyn\u00e9cologues et Obst\u00e9triciens Fran\u00e7ais. Clinical practice guidelines. J. Gynecol. Obstet. Biol. Reprod. 34, 513 (2005).","DOI":"10.1016\/S0368-2315(05)82867-4"},{"key":"46574_CR16","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1097\/AOG.0000000000001115","volume":"126","author":"EF Werner","year":"2015","unstructured":"Werner, E. F., Hauspurg, A. K. & Rouse, D. J. A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States. Obstet. Gynecol. 126, 1242\u20131250 (2015).","journal-title":"Obstet. Gynecol."},{"key":"46574_CR17","doi-asserted-by":"crossref","unstructured":"Roberge, S., Bujold, E. & Nicolaides, K. H. Meta-analysis on the eff ect of aspirin use for prevention of preeclampsia onplacental abruption and antepartum hemorrhage. Am. J. Obstet. Gynecol. 218, 483\u2013489 (2018).","DOI":"10.1016\/j.ajog.2017.12.238"},{"key":"46574_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3389\/fphar.2016.00440","volume":"7","author":"H Lei","year":"2016","unstructured":"Lei, H., Gao, Q., Liu, S.-R. & Xu, J. The benefit and safety of aspirin for primary prevention of ischemic stroke: A meta-analysis of randomized trials. Front. Pharmacol. 7, 440 (2016).","journal-title":"Front. Pharmacol."},{"key":"46574_CR19","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1001\/jama.2012.5034","volume":"307","author":"G De Berardis","year":"2012","unstructured":"De Berardis, G. et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 307, 2286\u20132294 (2012).","journal-title":"JAMA"},{"key":"46574_CR20","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/apt.14079","volume":"45","author":"W-C Chen","year":"2017","unstructured":"Chen, W.-C. et al. The risk of lower gastrointestinal bleeding in low-dose aspirin users. Aliment. Pharmacol. Ther. 45, 1542\u20131550 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"46574_CR21","doi-asserted-by":"crossref","unstructured":"Leonhardt, A. et al. Low-dose aspirin in pregnancy: maternal and neonatal aspirin concentrations and neonatalprostanoid formation. Pediatrics 111, e77\u2013e81 (2003).","DOI":"10.1542\/peds.111.1.e77"},{"key":"46574_CR22","doi-asserted-by":"crossref","unstructured":"Atallah, A. et al. Aspirin for prevention of preeclampsia. Drugs 77, 1819\u20131831 (2017).","DOI":"10.1007\/s40265-017-0823-0"},{"key":"46574_CR23","doi-asserted-by":"crossref","unstructured":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools forpharmacoepidemiology. Pharmacoepidemiol. Drug Saf. 26, 954\u2013962 (2017).","DOI":"10.1002\/pds.4233"},{"key":"46574_CR24","doi-asserted-by":"crossref","unstructured":"Blangis, F. et al. Maternal, prenatal and postnatal risk factors for early child physical abuse: a French nationwide cohort study. Lancet Reg. Health Eur. 42, 100929 (2024).","DOI":"10.1016\/j.lanepe.2024.100921"},{"key":"46574_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.0006-341X.2000.00779.x","volume":"56","author":"JM Robins","year":"2000","unstructured":"Robins, J. M. & Finkelstein, D. M. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 56, 779\u2013788 (2000).","journal-title":"Biometrics"},{"key":"46574_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v043.i13","volume":"43","author":"WM van der Wal","year":"2011","unstructured":"van der Wal, W. M. & Geskus, R. B. ipw: An R package for inverse probability weighting. J. Stat. Softw. 43, 1\u201323 (2011).","journal-title":"J. Stat. Softw."},{"key":"46574_CR27","unstructured":"Therneau, T. M. A package for survival analysis in R. R package version 3.5-0. Available at: https:\/\/CRAN.R-project.org\/package=survival (accessed 2026)."},{"key":"46574_CR28","doi-asserted-by":"crossref","unstructured":"Lumley, T. & Scott, A. Fitting regression models to survey data. Stat. Sci. 32, 265\u2013278 (2017).","DOI":"10.1214\/16-STS605"},{"key":"46574_CR29","doi-asserted-by":"crossref","unstructured":"Duley, L. et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev. CD004659 (2019).","DOI":"10.1002\/14651858.CD004659.pub3"},{"key":"46574_CR30","unstructured":"Pierron, A. et al. Evaluation of the metrological quality of medico-administrative data for perinatal indicators: a pilotstudy in three university hospitals. Rev. Epidemiol. Sante Publique 63, 237\u2013246 (2015)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46574-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46574-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46574-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:37:05Z","timestamp":1781480225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46574-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46574"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46574-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted under AP-HP\u2019s permanent authorization to access SNDS data, granted through Decree No. 2016\u20131871 of 26 December 2016, articles R.1461\u201313 and R.1461\u201314 of the French Public Health Code, and CNIL decision No. 2016\u2013316. All SNDS data used in this study were pseudonymized by CNAM prior to access. In accordance with this regulatory framework, additional approval from CESREES or CNIL was not required. The study was registered in the Health Data Hub\u2019s registry for SNDS-based research under reference 27827609. Informed consent was waived because the study relied exclusively on pseudonymized administrative data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"18467"}}